Shares of Reviva Pharmaceuticals Holdings, Inc. (RVPH) are rising more than 7% Thursday morning after the company announced positive safety data from the drug-drug interaction study of its drug candidate brilaroxazine.
Brilaroxazine is a serotonin/dopamine modulator in Phase 3 study for the treatment of schizophrenia.
Topline data from the Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia is expected in mid-2023.
RVPH, currently at $4.33, has traded in the range of 0.53-6.10 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.